GO:0070412 R-SMAD binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070412 (R-SMAD binding) is a molecular function describing the binding of a protein to a receptor-regulated SMAD (R-SMAD) signaling protein.
• R-SMADs (e.g., SMAD1, SMAD2, SMAD3, SMAD5, SMAD8) are direct substrates of type I TGF-beta family receptors and are central to TGF-beta/BMP signal transduction.
• Proteins that bind R-SMADs include SMAD4, SMAD7, Ski, SnoN, and CREB-binding protein (CBP), which modulate complex assembly, stability, and transcriptional output.
• R-SMAD binding is highly regulated by competition, post-translational modifications, and subcellular localization, controlling the intensity and duration of signaling.
• Dysregulated R-SMAD binding is implicated in cancer, fibrosis, and developmental disorders, making it a target for therapeutic intervention.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of R-SMAD binding interfaces and their functional consequences.
Description
GO:0070412, R-SMAD binding, is a molecular function defined as binding to a receptor-regulated SMAD (R-SMAD) signaling protein. R-SMADs are intracellular effectors of the transforming growth factor-beta (TGF-beta) superfamily, which includes TGF-beta, activin, and bone morphogenetic protein (BMP) ligands. Upon ligand binding, type I receptors phosphorylate R-SMADs, enabling them to form heteromeric complexes with the common mediator SMAD4 and translocate to the nucleus to regulate transcription. Proteins that physically interact with R-SMADs are critical for shaping signaling outcomes, and their binding is a key node for signal integration and crosstalk. Research into R-SMAD binding has revealed a complex network of interactions that determine cell fate, proliferation, differentiation, and apoptosis. For example, the inhibitory SMAD7 binds R-SMADs to block their phosphorylation and subsequent signaling, while transcriptional co-activators like CBP compete with repressors such as Ski for R-SMAD binding to modulate gene expression. Structural studies have elucidated the molecular details of R-SMAD interactions, providing a framework for understanding how mutations or dysregulation contribute to disease. Given its central role in TGF-beta signaling, R-SMAD binding is a focal point for biomedical research, with implications for cancer, fibrosis, and developmental disorders. This article provides a comprehensive overview of the ontology, mechanisms, key genes, and experimental approaches to study R-SMAD binding, optimized for researchers and AI-driven knowledge retrieval.
R-SMAD binding At A Glance
| GO ID | GO:0070412 |
|---|---|
| GO term | R-SMAD binding |
| Ontology | molecular_function |
| Synonym | pathway restricted SMAD binding; pathway-restricted SMAD binding; receptor regulated SMAD binding; receptor-regulated SMAD binding |
| Definition | Binding to a receptor-regulated SMAD signaling protein. |
| Major function | Mediates protein-protein interactions that regulate TGF-beta/BMP signaling by targeting R-SMADs for complex formation, modification, or degradation. |
| Related proteins | SMAD1, SMAD2, SMAD3, SMAD5, SMAD8 (R-SMADs); SMAD4 (co-SMAD); SMAD7 (I-SMAD); Ski; SnoN; CBP. |
| Signaling pathway | TGF-beta superfamily signaling (TGF-beta, activin, BMP). |
| Disease relevance | Cancer, fibrosis, developmental disorders, and wound healing. |
What Is GO:0070412?
R-SMAD binding (GO:0070412) is the molecular function of selectively interacting with a receptor-regulated SMAD (R-SMAD) protein. R-SMADs are a subclass of SMAD proteins that are directly phosphorylated and activated by type I serine/threonine kinase receptors of the TGF-beta superfamily. This binding event is a prerequisite for the assembly of functional SMAD complexes that transmit signals from the cell surface to the nucleus, thereby regulating gene expression.
Why Is R-SMAD binding Important in Cell Biology?
R-SMAD binding is a critical molecular function that governs the specificity and intensity of TGF-beta superfamily signaling, which controls a vast array of cellular processes including proliferation, differentiation, migration, and apoptosis. Dysregulation of these interactions is a hallmark of many diseases, particularly cancer and fibrosis, where aberrant TGF-beta signaling promotes tumor progression, epithelial-mesenchymal transition, and tissue scarring. Understanding the precise binding mechanisms offers opportunities for therapeutic intervention, such as designing inhibitors that block pathological R-SMAD interactions.
• Controls cell growth and differentiation by mediating TGF-beta/BMP signal transduction.
• Regulates developmental processes such as embryogenesis and organogenesis.
• Implicated in cancer progression, including tumor suppression and metastasis.
• Plays a key role in fibrosis and wound healing by activating fibroblasts.
• Modulates immune responses and inflammation through TGF-beta signaling.
• Serves as a target for small-molecule inhibitors and biologics in drug discovery.
• Provides a paradigm for understanding protein-protein interaction networks.
• Essential for maintaining tissue homeostasis and preventing unchecked proliferation.
• Involved in stem cell maintenance and differentiation.
• Dysregulation linked to developmental disorders and cardiovascular diseases.
What Happens During R-SMAD binding?
Ligand-Induced Receptor Activation and R-SMAD Phosphorylation
In simple terms: A signal molecule outside the cell binds to receptors, causing them to activate and tag R-SMAD proteins with phosphate groups.
TGF-beta superfamily ligands bind to type II receptors, which recruit and phosphorylate type I receptors. The activated type I receptors then phosphorylate R-SMADs at their C-terminal SXS motif, creating docking sites for downstream interactions. This phosphorylation is a prerequisite for R-SMAD binding to co-SMADs and other regulatory proteins.
Formation of R-SMAD/SMAD4 Complexes
In simple terms: Activated R-SMADs pair up with a partner protein called SMAD4 to form a team that can enter the nucleus.
Phosphorylated R-SMADs form heteromeric complexes with the common mediator SMAD4. Structural studies have revealed that the MH2 domains of R-SMADs and SMAD4 interact through a conserved interface, enabling the formation of a heterotrimer that is essential for nuclear translocation and transcriptional regulation. This assembly is a direct consequence of R-SMAD binding activity.
Regulation by Inhibitory SMADs and Other Binding Partners
In simple terms: Other proteins can grab onto R-SMADs to block or modify the signal.
Inhibitory SMAD7 binds to R-SMADs and competes with SMAD4, preventing complex formation and promoting receptor degradation. Similarly, the transcriptional repressor Ski and its homolog SnoN bind to R-SMADs to disrupt functional complexes, while co-activators like CBP compete for the same binding surface to enhance transcription. This competitive binding fine-tunes signaling output.
Nuclear Translocation and Transcriptional Regulation
In simple terms: The R-SMAD team moves into the cell nucleus, where it turns genes on or off.
Once in the nucleus, R-SMAD complexes bind to DNA via sequence-specific transcription factors and recruit co-regulators to modulate target gene expression. The binding of R-SMADs to various nuclear proteins, including CBP/p300 and Ski, determines whether genes are activated or repressed, thereby controlling cellular responses.
Termination and Degradation of R-SMAD Complexes
In simple terms: The signal is shut off when R-SMADs are tagged for destruction or recycled.
R-SMAD binding also targets these proteins for ubiquitination and proteasomal degradation. For example, the E3 ubiquitin ligase Smurf2 binds to R-SMADs via SMAD7, leading to their degradation and termination of signaling. Autophagic degradation of SQSTM1 has been shown to influence fibroblast activation, indirectly affecting TGF-beta/SMAD signaling.
Key Genes Involved in GO:0070412 R-SMAD binding
The following genes encode proteins that either are R-SMADs or bind to them, playing critical roles in TGF-beta superfamily signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD1 | R-SMAD activated by BMP receptors; binds SMAD4 | BMP signaling, bone development, cancer |
| SMAD2 | R-SMAD activated by TGF-beta/activin receptors | TGF-beta signaling, embryonic development, cancer |
| SMAD3 | R-SMAD activated by TGF-beta/activin receptors | TGF-beta signaling, fibrosis, cancer |
| SMAD4 | Co-SMAD; binds activated R-SMADs | Common mediator, tumor suppressor |
| SMAD5 | R-SMAD activated by BMP receptors | BMP signaling, angiogenesis |
| SMAD8 | R-SMAD activated by BMP receptors | BMP signaling, development |
| SMAD7 | Inhibitory SMAD; binds R-SMADs to block signaling | Negative regulation, cancer, fibrosis |
| SKI | Transcriptional repressor; binds R-SMADs | Oncogene, TGF-beta antagonism |
| SNO N | Ski-related; stabilizes SMAD3/SMAD4 complex | TGF-beta signaling modulation |
| CREBBP | Transcriptional co-activator; binds R-SMADs | Epigenetic regulation, cancer |
| EP300 | Histone acetyltransferase; binds R-SMADs | Transcriptional activation, cancer |
| SMURF2 | E3 ubiquitin ligase; binds R-SMADs via SMAD7 | Degradation of SMADs, signaling termination |
| SQSTM1 | Autophagy receptor; affects TGF-beta signaling | Wound healing, fibrosis |
| TGFBR1 | Type I receptor; phosphorylates R-SMADs | TGF-beta signaling, cancer |
| TGFBR2 | Type II receptor; activates type I receptor | TGF-beta signaling, cancer |
| ACVR1 | Type I receptor; phosphorylates R-SMADs | BMP signaling, development |
| BMPR1A | Type I receptor; phosphorylates R-SMADs | BMP signaling, bone formation |
How Is R-SMAD binding Regulated?
R-SMAD binding is regulated at multiple levels. Post-translational modifications of R-SMADs, such as phosphorylation and ubiquitination, modulate their interactions with binding partners. Competitive binding among co-activators and co-repressors, such as CBP and Ski, determines the transcriptional outcome. Additionally, the inner nuclear membrane phosphatase complex can suppress TGF-beta/SMAD signaling by dephosphorylating R-SMADs. Autophagic degradation of SQSTM1 has been shown to affect fibroblast activation and wound healing, indirectly influencing R-SMAD binding dynamics.
R-SMAD binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD4 | Pancreatic cancer, colorectal cancer | Knockout in cancer cell lines (e.g., PANC-1) |
| SMAD2/3 | Fibrosis, breast cancer | Point mutation in binding interface |
| SMAD7 | Inflammatory bowel disease, fibrosis | Overexpression in fibroblasts |
| SKI | Cancer (e.g., melanoma) | Knockout in melanoma cells |
| SQSTM1 | Wound healing, Paget's disease | Knockout in fibroblasts |
Cancer
Dysregulated R-SMAD binding is frequently observed in cancer. Mutations in SMAD4 or SMAD2/3 disrupt complex formation, leading to uncontrolled cell proliferation. Overexpression of inhibitory proteins like SMAD7 or Ski can block TGF-beta-mediated tumor suppression, promoting oncogenesis. Targeting R-SMAD interactions is a potential therapeutic strategy.
Fibrosis
Persistent TGF-beta signaling drives fibrosis by activating fibroblasts and promoting extracellular matrix deposition. R-SMAD binding is central to this process; for example, autophagic degradation of SQSTM1 enhances fibroblast activation and accelerates wound healing, implicating R-SMAD interactions in fibrotic diseases. Inhibiting R-SMAD binding could mitigate fibrosis.
Developmental Disorders
Proper R-SMAD binding is essential for embryonic development. Mutations in BMP receptors or R-SMADs that impair binding lead to developmental abnormalities, such as skeletal defects and cardiovascular malformations. Studies in Drosophila have shown that R-SMAD competition controls activin receptor output, highlighting evolutionary conservation.
From R-SMAD binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of R-SMAD binding affect TGF-beta target gene expression? | Knockout of SMAD4 in cell lines |
| How does a point mutation in the SMAD3 MH2 domain alter complex formation? | Point mutation knock-in in SMAD3 |
| Can a tagged R-SMAD be used to map binding partners? | Knock-in of FLAG-tagged SMAD2 |
| Does overexpression of SMAD7 inhibit fibrosis? | Overexpression of SMAD7 in fibroblasts |
| What is the role of SQSTM1 in R-SMAD binding during wound healing? | Knockout of SQSTM1 in keratinocytes |
| How does R-SMAD competition control activin signaling? | Overexpression of dominant-negative R-SMAD in Drosophila |
How to Study the R-SMAD binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interactions | Validate R-SMAD binding in cell lysates |
| GST pull-down | Direct binding to recombinant proteins | Map binding domains |
| X-ray crystallography | 3D structure of complexes | Determine binding interface |
| Luciferase reporter | Transcriptional activity | Assess functional impact of binding |
| CRISPR knockout | Loss of gene function | Study signaling pathway |
| CRISPR knock-in | Tagged or mutant protein expression | Track localization or interactions |
| RNA-seq | Global gene expression changes | Identify R-SMAD target genes |
| Proteomics (AP-MS) | Binding partners in vivo | Discover novel R-SMAD interactors |
Co-Immunoprecipitation (Co-IP) and Pull-Down Assays
Co-IP using antibodies against R-SMADs or their binding partners can confirm physical interactions. GST pull-down assays with recombinant proteins are used to map binding domains. These methods are fundamental for validating R-SMAD binding events.
Structural Biology (X-ray Crystallography, Cryo-EM)
High-resolution structures of R-SMAD complexes, such as the SMAD3/SMAD4 heterotrimer, reveal the molecular details of binding interfaces. These structures guide mutagenesis studies and drug design.
Transcriptional Reporter Assays
Luciferase reporters driven by TGF-beta-responsive promoters (e.g., SBE-luc) measure the functional impact of R-SMAD binding on gene expression. This is useful for screening inhibitors or mutations.
CRISPR-Based Genome Editing
Knockout, point mutation, and knock-in models allow precise manipulation of genes encoding R-SMADs or their binding partners. These models are essential for dissecting causal roles in signaling and disease.
How CRISPR Can Be Used to Study GO:0070412 R-SMAD binding
Knockout
CRISPR knockout of genes encoding R-SMADs or their binding partners (e.g., SMAD4, SMAD7) can abolish specific interactions, revealing their contribution to signaling. For example, SMAD4 knockout cell lines are widely used to study TGF-beta resistance in cancer.
Point Mutation
Introducing point mutations in the binding interface of R-SMADs (e.g., SMAD3) can disrupt specific interactions without affecting overall protein stability. This approach helps dissect the functional significance of individual binding events.
Knock-in
Knock-in of epitope-tagged R-SMADs (e.g., FLAG-SMAD2) allows for endogenous-level expression and interaction studies. This is valuable for mapping dynamic binding in live cells.
Overexpression
Overexpression of wild-type or mutant R-SMADs or their regulators (e.g., SMAD7) can amplify or inhibit signaling, providing insights into dosage effects and competition.
How EDITGENE Supports R-SMAD binding Research
Researchers studying R-SMAD binding-related genes often need to determine whether a candidate gene is causally involved in signaling or disease. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling functional validation of R-SMAD interactions.
Contact EDITGENE today to design your custom CRISPR model for R-SMAD binding research.
Frequently Asked Questions About R-SMAD binding
What is R-SMAD binding?
R-SMAD binding (GO:0070412) is a molecular function where a protein interacts with a receptor-regulated SMAD (R-SMAD), a key step in TGF-beta superfamily signaling.
What genes are involved in R-SMAD binding?
Key genes include SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD7, SKI, SNO N, and CREBBP, among others.
How does R-SMAD binding regulate TGF-beta signaling?
It mediates the formation of R-SMAD/SMAD4 complexes, which translocate to the nucleus and control gene expression. Inhibitory proteins like SMAD7 compete for binding to block signaling.
What diseases are associated with R-SMAD binding?
Dysregulation is linked to cancer, fibrosis, and developmental disorders.
What methods are used to study R-SMAD binding?
Common methods include co-immunoprecipitation, GST pull-down, structural biology, and CRISPR-based genome editing.
Can CRISPR be used to study R-SMAD binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of R-SMAD interactions.
What is the role of SMAD7 in R-SMAD binding?
SMAD7 binds to R-SMADs and prevents their phosphorylation and complex formation with SMAD4, acting as a negative regulator.
How does Ski regulate R-SMAD binding?
Ski competes with co-activators like CBP for binding to R-SMADs, thereby repressing TGF-beta target genes.
What is the structural basis of R-SMAD binding?
Structures of SMAD3/SMAD4 complexes reveal that the MH2 domains interact through a conserved interface, which is critical for signaling.
Why is R-SMAD binding important for cancer research?
Altered R-SMAD binding can lead to uncontrolled cell growth and metastasis, making it a target for cancer therapy.
Conclusion
R-SMAD binding (GO:0070412) is a fundamental molecular function that orchestrates TGF-beta superfamily signaling, influencing a wide range of biological processes and diseases. Understanding the precise mechanisms, key genes, and regulatory networks is essential for developing targeted therapies. EDITGENE's advanced CRISPR services empower researchers to create custom cell models and screen for novel modulators of R-SMAD binding, accelerating discoveries in cancer, fibrosis, and developmental biology.
References
- 1. Xu Y et al.. 2025. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing.. Autophagy 21(11):2401-2421 PMID: 40400126
- 2. Walldén K et al.. 2017. SnoN Stabilizes the SMAD3/SMAD4 Protein Complex.. Sci Rep 7:46370 PMID: 28397834
- 3. Chacko BM et al.. 2004. Structural basis of heteromeric smad protein assembly in TGF-beta signaling.. Mol Cell 15(5):813-23 PMID: 15350224
- 4. Ji Z et al.. 2025. Suppression of TGF-β/SMAD signaling by an inner nuclear membrane phosphatase complex.. Nat Commun 16(1):3474 PMID: 40216785
- 5. Clarke DC et al.. 2006. Systems theory of Smad signalling.. Syst Biol (Stevenage) 153(6):412-24 PMID: 17186703
- 6. Chen W et al.. 2007. Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling.. J Biol Chem 282(15):11365-76 PMID: 17283070
- 7. Yan X et al.. 2016. Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling.. J Biol Chem 291(1):382-92 PMID: 26555259
- 8. Peterson AJ et al.. 2012. R-Smad competition controls activin receptor output in Drosophila.. PLoS One 7(5):e36548 PMID: 22563507
